Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
        • Real stories
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Careers and studies
        • Contact
  • Donate
    Centenary Institute > Melanoma Oncology and Immunology Program

Melanoma Oncology and Immunology Program

The current focus of melanoma research at the Centenary Institute is to better understand the resistance of certain melanoma to new treatments. We are particularly interested in the role of epigenetic regulation in resistance and the role of new drugs targeting these mechanisms in treatment of melanoma.

With the incidence of melanoma in Australia is in excess of 12,000 each year this area of research is of high importance to the community. Melanoma accounts for approximately 1,500 deaths per annum in Australia with about 450 of these being in NSW. Prevalence over a five year period is in excess of 45,000 people.

Our approach is to conduct translational research with a focus on resistance mechanisms.  We continue to look at methods of improving the landscape of treatments with immunotherapy and other targeted treatments.

Over the past five years there has been significant breakthrough in treatment approaches with two new options showing promise to reduce the mortality from the disease. One is the use of treatments targeted to aberrant signal pathways in melanoma. The second is immunotherapy based on inhibition of immune checkpoints with monoclonal antibodies. Read below on our projects that look into these specific areas.

Increasing responses to immune checkpoint inhibitors

  • Overcoming T cell exhaustion during immunotherapy with immune checkpoint inhibitors by metabolic approaches
  • Effects of epigenetic regulators on PD-L1 expression, antigen expression and immune responses
  • Combining chemotherapy with checkpoint inhibitors to increase immune responses against resistant melanoma

Resistance to targeted therapies

  • Repurposing chemotherapy to activate innate death mechanisms in targeted therapy resistant melanoma
  • EZH2 inhibitors and combinations with other drugs in treatment resistant melanoma
  • BET inhibitors and combination with other drugs in treatment resistant melanoma

Melanoma Epigenetic Lab

  • The role of histone and chromatin modifier’s in melanoma progression and treatment resistance.
  • Identifying novel epigenetic regulators of targeted therapy and immunotherapy resistance.
  • Investigating sex differences in X-linked epigenetic regulators of melanoma.

Head

Professor Peter Hersey

Head of Melanoma Oncology and Immunology

Themes

  • Cancer

    Cancer

Head

  • Professor Peter Hersey

    Head of Melanoma Oncology and Immunology

    Phone number Phone Number +61 2 9565 6130

    Email Email p.hersey@centenary.org.au

Research Fields

  • Melanoma

Topics

  • Chronic diseases ,

Expertise

  • Epigenetics ,

Publications

Recent publications

Search amongst our repository

all publications

For access to all Publications via Pub Med.

Increasing responses to immune checkpoint inhibitors

  • Overcoming T cell exhaustion during immunotherapy with immune checkpoint inhibitors by metabolic approaches
  • Effects of epigenetic regulators on PD-L1 expression, antigen expression and immune responses
  • Combining chemotherapy with checkpoint inhibitors to increase immune responses against resistant melanoma

Resistance to targeted therapies

  • Repurposing chemotherapy to activate innate death mechanisms in targeted therapy resistant melanoma
  • EZH2 inhibitors and combinations with other drugs in treatment resistant melanoma
  • BET inhibitors and combination with other drugs in treatment resistant melanoma

Melanoma Epigenetic Lab

  • The role of histone and chromatin modifier’s in melanoma progression and treatment resistance.
  • Identifying novel epigenetic regulators of targeted therapy and immunotherapy resistance.
  • Investigating sex differences in X-linked epigenetic regulators of melanoma.

Head

Professor Peter Hersey

Head of Melanoma Oncology and Immunology

News

  • New discovery tackles treatment-resistant melanoma

    Researchers from the Centenary Institute have developed a new approach to fighting melanomas that fail to respond – or are resistant – to standard treatments.
    Date 26 Oct 2021
  • Meet Professor Peter Hersey

    Hi, I’m Professor Hersey and I am the Head of the Melanoma Oncology and Immunology Program at Centenary.
    Date 24 Aug 2018
View all

Twitter

Tweets by CentenaryInst Follow us (links open in a new window)

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram